advertisement
Abstract #47813 Published in IGR 13-4
Effect of brimonidine on corneal thickness
Grueb M; Mielke J; Rohrbach JM; Schlote TJournal of Ocular Pharmacology and Therapeutics 2011; 27: 503-509
Purpose: Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication that is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors, there are only few studies available on the impact brimonidine has on the cornea. Methods: Twenty healthy test persons (12 female and 8 male subjects)-mean age about 33 years (22 to 38 years)-were tested in a double-blind, prospective, randomized study. Intraocular pressure as well as epithelial, stromal, and endothelial thickness was measured before, at 25 days while, and at 5 days after administration of brimonidine 0.1% eye drops twice daily. To check the impact of this medication, placebo (proper solution of preservative) eye drops were administered to the other eye twice daily. Results: Administration of brimonidine 0.1% resulted in a reduction of intraocular pressure from an initial value of 14 to 9 mmHg after 5 days (P=0.001) as well as an increase in total corneal thickness from 556 (mu)m from the time of the baseline examination to 578 (mu)m (P=0.001), an increase of epithelial thickness from 58 to 66(mu)m (P<0.001), and stromal thickness from 488 to 502 (mu)m (P=0.008) after 2 days each. Another 2 days later, total corneal thickness was 559 (mu)m (P=0.276), epithelial thickness 56 (mu)m (P=0.561), and stromal thickness 493 (mu)m (P=0.315), which means that the values had returned more or less toward the initial values measured. In contrast, endothelial thickness did not vary following administration of brimonidine 0.1% (P=0.965). With treatment with brimonidine 0.1%, mean intraocular pressure in thin corneas (<556(mu)m) was lower than in the thick corneas (>556 (mu)m, P=0.018). Conclusions: Topical administration of brimonidine 0.1% results in a reversible increase in corneal thickness. The question whether this increase is of clinical significance and whether it is the result of epithelial and/or endothelial receptor stimulation cannot be finally answered at the present time. (copyright) 2011 Mary Ann Liebert, Inc.
M. Grueb. Augenarztpraxis Breisach, Neutorplatz 6, D-79206 Breisach am Rhein, Germany. Email: matthias.grueb@web.de
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)
